GENOMED INC Form 8-K May 06, 2005

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
MAY 3, 2005

GENOMED, INC. (Exact name of registrant as specified in its charter)

FLORIDA	000-49720	43-1916702
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS Employer Identification Number)

ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

(a) The registrant's independent auditor, Rubin, Brown, Gornstein & Co., LLP ("RBG") declined to stand for reelection, and, effective May 3, 2005, RBG was dismissed.

The report of RBG on the financial statements for the year ended December 31, 2004 contained no adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principle, except that the report for the year ended December 31, 2004 contained an explanatory paragraph expressing doubt about the Registrant's ability to continue as a going concern.

RBG served as the auditor during the most recent fiscal year of the registrant (2004), and during that time there has been no disagreement with RBG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which if not resolved

Edgar Filing: GENOMED INC - Form 8-K

to the satisfaction of RBG, would have caused it to make reference to the subject matter of the disagreement in connection with its report.

The registrant has authorized RBG to respond fully to any inquiries of its new auditor concerning any issue relating to the registrant's accounting principles or practices or financial reporting, the registrant's financial statements or RBG's audit thereof or audit opinions thereon.

The registrant has provided a copy of the disclosures in this report to RBG. Any letter from RBG pursuant to paragraph (a)(3) of Regulation S-K will be supplied by amendment.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

GenoMed, Inc.

Dated: May 6, 2005 By: /s/ Dr. David Moskowitz

Dr. David Moskowitz Chairman of the Board and Chief Executive Officer
